menu
    • menu
    [{"orgOrder":0,"company":"AIIMS","sponsor":"CSIR","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Undisclosed","year":"2021","type":"Not Applicable","leadProduct":"BGR-34","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"AIIMS","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AIIMS \/ CSIR","highestDevelopmentStatusID":"12","companyTruncated":"AIIMS \/ CSIR"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Glibenclamide","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Remedy Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Remedy Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Glibenclamide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Remedy Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Remedy Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Glibenclamide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Remedy Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Remedy Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Glibenclamide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Remedy Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Remedy Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ammtek","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Glibenclamide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Ammtek","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Ammtek \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Ammtek \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Remedy Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Glibenclamide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Remedy Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Remedy Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Remedy Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Glibenclamide

    Menu

    Glibenclamide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ammtek

                            Country arrow
                            Antibody Engineering
                            Not Confirmed

                            Ammtek

                            Country arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glibenclamide

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Eton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Eton Acquires U.S. Rights to Amglidia (Glyburide Oral Suspension) for Diabetes

                            Details : Eton acquired the U.S. rights to Amglidia (glyburide oral suspension, known as glibenclamide in Europe) for the treatment of neonatal diabetes mellitus from AMMTeK.

                            Brand Name : Amglidia

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 25, 2024

                            Lead Product(s) : Glibenclamide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Eton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Remedy Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Remedy Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glibenclamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Remedy Pharma Advances CIRARA After FDA Guidance for Severe Stroke Treatment

                            Details : Cirara (glyburide), targets a critical regulator of cerebral edema, the SUR1-TRPM4 channel. By inhibiting this channel, it prevents this life-threatening edema in patients suffering from LHI.

                            Brand Name : Cirara

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 19, 2024

                            Lead Product(s) : Glibenclamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Remedy Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Remedy Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glibenclamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Remedy Gains FDA Orphan Designation for CIRARA in Ischemic Stroke

                            Details : Cirara (glibenclamide), targets a critical regulator of cerebral edema, the SUR1-TRPM4 channel. By inhibiting this channel, it prevents this life-threatening edema in patients suffering from LHI.

                            Brand Name : Cirara

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 22, 2024

                            Lead Product(s) : Glibenclamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Remedy Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Remedy Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glibenclamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Remedy’s Stroke Trial Shows Significant Effect at One Year

                            Details : Cirara (glibenclamide), targets a critical regulator of cerebral edema, the SUR1-TRPM4 channel. By inhibiting this channel, it prevents this life-threatening edema in patients suffering from LHI.

                            Brand Name : Cirara

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 01, 2024

                            Lead Product(s) : Glibenclamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Remedy Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Remedy Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glibenclamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Remedy Pharmaceuticals' CIRARA Shows Potential to Improve Ambulation in Stroke

                            Details : Cirara (glyburide), targets a critical regulator of cerebral edema, the SUR1-TRPM4 channel. By inhibiting this channel, it prevents this life-threatening edema in patients suffering from LHI.

                            Brand Name : Cirara

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 03, 2024

                            Lead Product(s) : Glibenclamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Remedy Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Remedy Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glibenclamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Remedy Pharmaceuticals Reclaims Stroke Drug Rights; Reports Phase 3 Study Results

                            Details : Cirara (glibenclamide), targets a critical regulator of cerebral edema, the SUR1-TRPM4 channel. By inhibiting this channel, it prevents this life-threatening edema in patients suffering from LHI.

                            Brand Name : Cirara

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 30, 2024

                            Lead Product(s) : Glibenclamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AIIMS

                            India arrow
                            Antibody Engineering
                            Not Confirmed

                            AIIMS

                            India arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BGR-34,Glibenclamide

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : CSIR

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AIIMS Researchers Find Ayurvedic-Allopathic Combo BGR-34 & Glibenclamide in Controlling Diabetes

                            Details : In the Animal experimental study, doctors have found that the pace of diabetes growth can be halted if allopathic drug is integrated with BGR-34, a herbal formulation enriched with antioxidant properties which stops bad cholesterol from accumulating in t...

                            Brand Name : BGR-34

                            Molecule Type : Undisclosed

                            Upfront Cash : Not Applicable

                            February 03, 2021

                            Lead Product(s) : BGR-34,Glibenclamide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : CSIR

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth